Science

Paolo Tarantino: The MSK Retrospective Experience With ADC Sequencing for MBC

Paolo Tarantino/X

May 31, 2025, 14:02

Paolo Tarantino: The MSK Retrospective Experience With ADC Sequencing for MBC

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“The MSK retrospective experience with ADC sequencing (T-DXd -> SG or viceversa) for MBC.

Among 85 patients included, 75% had a worse PFS with the second ADC, irrespective of the sequence. Confirms multiple reports of cross resistance between topo1 ADCs.”

Title: Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan

Authors: Nicholas Mai, Miriam M. Klar Lieberman, Emanuela Ferraro, Maria Bromberg, Yuan Chen, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Elaine M. Walsh, Joshua Z. Drago

You can read the Full Article on JCO Precision Oncology

Paolo Tarantino: The MSK Retrospective Experience With ADC Sequencing for MBC

More posts featuring Paolo Tarantino.

ADCs Breast Cancer cancer Elaine M. Walsh Emanuela Ferraro Joshua Z. Drago Maria Bromberg Miriam M. Klar Lieberman Nicholas Mai OncoDaily Oncology Paolo Tarantino Pedram Razavi Sarat Chandarlapaty Shanu Modi Yuan Chen

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Robin Zon: The Official End of My Term as ASCO President